Navigation Links
Stem cells shape up to their surroundings
Date:10/7/2010

oscale grooves, pits and ridges, and are particularly sensitive to the spacing and regularity of these features.

Nanotopographical responsiveness has been observed in diverse cell types including fibroblasts, osteoblasts, osteoclasts, endothelial, smooth muscle, epithelial, and epitenon cells. "This is intriguing from a biomaterials perspective," says McNamara, "as it demonstrates that surface features of just a few nanometres can influence how cells will respond to, and form tissue on, materials."

Stem cells detect surface features with a variety of mechanosensors, including integrin-linked focal adhesions. These respond to the mechanical constraints of the surface by inducing signalling cascades, such as the ERK-MAPK pathway. When the cell's rearranging cytoskeleton physically pulls on components of the cell's nucleus, this force works together with chemical signalling. Together these indirect (biochemical signal-mediated) and direct (force-mediated) factors can modulate nuclear components, altering gene expression to direct stem cell responses.

One interesting finding has been that topography can in some cases have the same effect as biochemical differentiation factors. The potential to eliminate the need for the latter opens the door to development of improved clinical prostheses with topographies that can directly modulate stem cell fate. In particular, the authors envisage applications involving engineered topography components for stem cells in regenerative medicine, for instance, in orthopaedics and dental implants. A combination of different topographies could be used to differentially functionalise implants for distinct applications, or demarcate particular "zones" within a single device.

Orthopaedic implants designed with specific regions tailored to integrate with bone and improve the chances of implant fixation might be seamlessly join other areas of the implant programmed to reduce excessive bony ingrowth, for exa
'/>"/>

Contact: Jayne Fairley
jayne.fairley@sagepub.co.uk
020-732-48719
SAGE Publications UK
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
2. NSF funds new Center for the Physics of Living Cells at Illinois
3. When cells go bad
4. The role of stem cells in renewing the cornea
5. Breast cancer cells recycle to escape death by hormonal therapy
6. Models of eel cells suggest electrifying possibilities
7. Scientists identify a molecule that coordinates the movement of cells
8. Form of Crohns disease traced to disabled gut cells
9. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
10. Researchers design artificial cells that could power medical implants
11. Stabilizing force for good communication between neurons and muscle cells found
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... July 8, 2015 Summary Pancreatic cancer ... fourth most fatal, with a mortality rate of 10.9 ... of pancreatic cancer patients has highlighted a significant need ... not being met by the current market. A ... products with varying molecule types and mechanisms of action, ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
(Date:7/7/2015)... DUBLIN , June 30, 2015 ... ) has announced the addition of the ... their offering. To this date, fingerprint ... biometric technology and fingerprint sensors are well developed. ... capacitive sensing technology. The domain of ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... by researchers at Queen Mary University of London collates data ... per cent of the births in England and Wales. Examples ... neural tube defects such as spina bifida, and limb malformations ... (PHE), the study is the most up-to-date and comprehensive of ...
... and the American Society for Cell Biology (ASCB) announced a ... ( LSE ). This partnership adds to GSA,s ... resources and research to its members and the public. ... in the life sciences and is renowned for its data-driven ...
... led by Charles D. Nichols, PhD, Associate Professor of ... successfully translated a new technology to better study behaviors ... tool Designer Receptors Exclusively Activated by Designer ... dose-dependently remotely control behaviors and physiological processes in the ...
Cached Biology News:1 baby in every 46 born with a congenital anomaly says new report 2Genetics Society of America joins editorial partnership for CBE-Life Sciences Education 2LSUHSC researchers develop new system to better study behavior, cell function 2
(Date:7/29/2015)... ... July 29, 2015 , ... ... CHRONO NIGHT Express Contouring Bi-Gel, a nighttime-specific product that targets fat cells for ... that are able to enter fat cells, inhibiting the formation of new fat. ...
(Date:7/28/2015)... A n ew UK company ... commercialising innovative medicines to transform patient quality of life and ... team; blue chip investor ... Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, announces that it ... blue chip institutional investors and simultaneously acquired a portfolio of ...
(Date:7/28/2015)... , July 28, 2015 Seahorse ... cell metabolism, is the provider of XF Technology ... all disease research areas. As the links between ... into cell metabolism is escalating rapidly.   ... by the Nature Publishing Group (NPG) featuring XF ...
(Date:7/28/2015)... NEW YORK , July 28, 2015 ... the Deerfield Healthcare Innovations Fund, L.P., which will invest ... therapeutic interventions in genetic diseases, cancer, and orphan diseases. ... that can transform how therapeutics are developed and improve ... The fund, one of the largest healthcare-focused venture funds ...
Breaking Biology Technology:Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3
... 19, 2012 RayBiotech, Inc. today announced that it ... core facilities at academic and government research institutes in ... the partnership program, core diagnostics facilities will be able ... component of their current services offerings at no cost ...
... 19, 2012  New data presented today studied the ... nitric oxide (NO) to patients being evaluated for ... privately held, advanced development-stage technology company, announced that ... Right Heart Catheterization (RHC) in subjects being evaluated ...
... Childhood obesity is a widespread global epidemic ... (NAFLD) [2] is now the leading cause of liver ... Liver Congress™ 2012 furthers this concern by showing that childhood ... the most common form of liver cancer [3] - ...
Cached Biology Technology:RayBiotech, Inc. Announces New Diagnostic Core Facility Partnering Program 2New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 2New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 3New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 4Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 2Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 3Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 4